NYSE:CBMCambrex Stock Price, Forecast & News Notice: This company has been marked as potentially delisted and may not be actively trading. Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Cambrex Co. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $59.99 0.00 (0.00 %) (As of 01/27/2020) Add Compare Share Today's Range$59.99Now: $59.99▼$59.9950-Day Range$59.99MA: $59.99▼$59.9952-Week Range$33.80Now: $59.99▼$60.29VolumeN/AAverage Volume218,726 shsMarket Capitalization$2.02 billionP/E Ratio21.66Dividend YieldN/ABeta2.14 ProfileAnalyst RatingsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. Its products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as finished dosage forms. The company serves generic drug companies; and companies that discover and commercialize small molecule human therapeutics. The company sells its products directly, as well as through independent agents. Cambrex Corporation was founded in 1981 and is headquartered in East Rutherford, New Jersey.Read More Beat the Market (BTM) Rank™ 1.0 Analyst's Opinion Consensus RatingCambrex has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $60.00, Cambrex has a potential upside of 0.0% from its current price of $59.99.Amount of Analyst CoverageCambrex has received no research coverage in the past 90 days. Previous Next 2.5 Community Rank Outperform VotesCambrex has received 309 “outperform” votes. (Add your “outperform” vote.)Underperform VotesCambrex has received 302 “underperform” votes. (Add your “underperform” vote.)Community SentimentCambrex has received 50.57% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Cambrex and other stocks. Vote “Outperform” if you believe CBM will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CBM will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldCambrex does not currently pay a dividend.Dividend GrowthCambrex does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cambrex insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.41% of the stock of Cambrex is held by insiders.Percentage Held by Institutions90.96% of the stock of Cambrex is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Cambrex is 21.66, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 14.55.Price to Earnings Ratio vs. SectorThe P/E ratio of Cambrex is 21.66, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 26.00.Price to Book Value per Share RatioCambrex has a P/B Ratio of 3.08. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 1.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.03 out of 5 stars Industry, Sector and Symbol Stock Exchange NYSE Industry Pharmaceutical preparations Sub-IndustryLife Sciences Tools & Services SectorMedical Current SymbolNYSE:CBM Previous Symbol CUSIP13201110 CIK820081 Webwww.cambrex.com Phone201-804-3000Debt Debt-to-Equity Ratio0.76 Current Ratio2.37 Quick Ratio1.70Price-To-Earnings Trailing P/E Ratio21.66 Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$532.09 million Price / Sales3.80 Cash Flow$3.91 per share Price / Cash Flow15.36 Book Value$19.48 per share Price / Book3.08Profitability EPS (Most Recent Fiscal Year)$2.77 Net Income$92.41 million Net Margins5.96% Return on Equity5.38% Return on Assets2.50%Miscellaneous Employees1,732 Outstanding Shares33,720,000Market Cap$2.02 billion Next Earnings DateN/A OptionableOptionable Receive CBM News and Ratings via Email Sign-up to receive the latest news and ratings for CBM and its competitors with MarketBeat's FREE daily newsletter. Cambrex (NYSE:CBM) Frequently Asked Questions Do Wall Street analysts recommend investors buy shares of Cambrex? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cambrex in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Cambrex. How were Cambrex's earnings last quarter? Cambrex Co. (NYSE:CBM) issued its quarterly earnings results on Thursday, August, 2nd. The biotechnology company reported $0.74 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.69 by $0.05. The biotechnology company had revenue of $152.05 million for the quarter, compared to analysts' expectations of $132.78 million. Cambrex had a return on equity of 5.38% and a net margin of 5.96%. The firm's revenue for the quarter was up 13.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.76 EPS. View Cambrex's earnings history. What price target have analysts set for CBM? 2 brokers have issued 12 month price objectives for Cambrex's stock. Their forecasts range from $60.00 to $60.00. On average, they expect Cambrex's stock price to reach $60.00 in the next year. This suggests a possible upside of 0.0% from the stock's current price. View analysts' price targets for Cambrex. Has Cambrex been receiving favorable news coverage? Media stories about CBM stock have been trending very negative recently, according to InfoTrie. The research group scores the sentiment of news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Cambrex earned a media sentiment score of -3.1 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near future. View the latest news aboutCambrex. Who are some of Cambrex's key competitors? Some companies that are related to Cambrex include Thermo Fisher Scientific (TMO), Illumina (ILMN), Agilent Technologies (A), Mettler-Toledo International (MTD), Bio-Rad Laboratories (BIO), Waters (WAT), PerkinElmer (PKI), BIO-TECHNE (TECH), Charles River Laboratories Intl. (CRL), Bruker (BRKR), Luminex (LMNX), Pacific Biosciences of California (PACB), Fluidigm (FLDM), Harvard Bioscience (HBIO) and aTyr Pharma (LIFE). View all competitors. What other stocks do shareholders of Cambrex own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cambrex investors own include Celgene (CELG), Illumina (ILMN), AbbVie (ABBV), CVS Health (CVS), NVIDIA (NVDA), Gilead Sciences (GILD), Intel (INTC), Broadcom (AVGO), Walt Disney (DIS) and Under Armour (UAA). Who are Cambrex's key executives? Cambrex's management team includes the following people: Mr. Steven M. Klosk, Pres, CEO & Director (Age 62)Mr. Gregory P. Sargen, Exec. VP of Corp. Devel. & Strategy and CFO (Age 53)Mr. Shawn P. Cavanagh, Exec. VP & COO (Age 53)Ms. Samantha M. Hanley, VP, Gen. Counsel & Corp. Sec. (Age 41)Mr. James G. Farrell, VP & Corp. Controller (Age 52) What is Cambrex's stock symbol? Cambrex trades on the New York Stock Exchange (NYSE) under the ticker symbol "CBM." What is Cambrex's stock price today? One share of CBM stock can currently be purchased for approximately $59.99. How big of a company is Cambrex? Cambrex has a market capitalization of $2.02 billion and generates $532.09 million in revenue each year. The biotechnology company earns $92.41 million in net income (profit) each year or $2.77 on an earnings per share basis. Cambrex employs 1,732 workers across the globe. What is Cambrex's official website? The official website for Cambrex is www.cambrex.com. How can I contact Cambrex? Cambrex's mailing address is ONE MEADOWLANDS PLZ, EAST RUTHERFORD NJ, 07073. The biotechnology company can be reached via phone at 201-804-3000 or via email at [email protected] This page was last updated on 5/27/2020 by MarketBeat.com Staff
